188 related articles for article (PubMed ID: 32679452)
1. PFKFB3 inhibitors as potential anticancer agents: Mechanisms of action, current developments, and structure-activity relationships.
Wang Y; Qu C; Liu T; Wang C
Eur J Med Chem; 2020 Oct; 203():112612. PubMed ID: 32679452
[TBL] [Abstract][Full Text] [Related]
2. Discovery and Structure-Activity Relationships of N-Aryl 6-Aminoquinoxalines as Potent PFKFB3 Kinase Inhibitors.
Boutard N; Białas A; Sabiniarz A; Guzik P; Banaszak K; Biela A; Bień M; Buda A; Bugaj B; Cieluch E; Cierpich A; Dudek Ł; Eggenweiler HM; Fogt J; Gaik M; Gondela A; Jakubiec K; Jurzak M; Kitlińska A; Kowalczyk P; Kujawa M; Kwiecińska K; Leś M; Lindemann R; Maciuszek M; Mikulski M; Niedziejko P; Obara A; Pawlik H; Rzymski T; Sieprawska-Lupa M; Sowińska M; Szeremeta-Spisak J; Stachowicz A; Tomczyk MM; Wiklik K; Włoszczak Ł; Ziemiańska S; Zarębski A; Brzózka K; Nowak M; Fabritius CH
ChemMedChem; 2019 Jan; 14(1):169-181. PubMed ID: 30378281
[TBL] [Abstract][Full Text] [Related]
3. Targeting the Warburg Effect in cancer; relationships for 2-arylpyridazinones as inhibitors of the key glycolytic enzyme 6-phosphofructo-2-kinase/2,6-bisphosphatase 3 (PFKFB3).
Brooke DG; van Dam EM; Watts CK; Khoury A; Dziadek MA; Brooks H; Graham LJ; Flanagan JU; Denny WA
Bioorg Med Chem; 2014 Feb; 22(3):1029-39. PubMed ID: 24398380
[TBL] [Abstract][Full Text] [Related]
4. Small molecule inhibition of 6-phosphofructo-2-kinase suppresses t cell activation.
Telang S; Clem BF; Klarer AC; Clem AL; Trent JO; Bucala R; Chesney J
J Transl Med; 2012 May; 10():95. PubMed ID: 22591674
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of 6-phosphofructo-2-kinase (PFKFB3) suppresses glucose metabolism and the growth of HER2+ breast cancer.
O'Neal J; Clem A; Reynolds L; Dougherty S; Imbert-Fernandez Y; Telang S; Chesney J; Clem BF
Breast Cancer Res Treat; 2016 Nov; 160(1):29-40. PubMed ID: 27613609
[TBL] [Abstract][Full Text] [Related]
6. Structure-based development of small molecule PFKFB3 inhibitors: a framework for potential cancer therapeutic agents targeting the Warburg effect.
Seo M; Kim JD; Neau D; Sehgal I; Lee YH
PLoS One; 2011; 6(9):e24179. PubMed ID: 21957443
[TBL] [Abstract][Full Text] [Related]
7. Discover potential inhibitors for PFKFB3 using 3D-QSAR, virtual screening, molecular docking and molecular dynamics simulation.
Bao Y; Zhou L; Dai D; Zhu X; Hu Y; Qiu Y
J Recept Signal Transduct Res; 2018; 38(5-6):413-431. PubMed ID: 30822195
[TBL] [Abstract][Full Text] [Related]
8. Phosphorylation of the 6-phosphofructo-2-kinase/fructose 2,6-bisphosphatase/PFKFB3 family of glycolytic regulators in human cancer.
Bando H; Atsumi T; Nishio T; Niwa H; Mishima S; Shimizu C; Yoshioka N; Bucala R; Koike T
Clin Cancer Res; 2005 Aug; 11(16):5784-92. PubMed ID: 16115917
[TBL] [Abstract][Full Text] [Related]
9. Targeting 6-phosphofructo-2-kinase (PFKFB3) as a therapeutic strategy against cancer.
Clem BF; O'Neal J; Tapolsky G; Clem AL; Imbert-Fernandez Y; Kerr DA; Klarer AC; Redman R; Miller DM; Trent JO; Telang S; Chesney J
Mol Cancer Ther; 2013 Aug; 12(8):1461-70. PubMed ID: 23674815
[TBL] [Abstract][Full Text] [Related]
10. Treatment against glucose-dependent cancers through metabolic PFKFB3 targeting of glycolytic flux.
Jones BC; Pohlmann PR; Clarke R; Sengupta S
Cancer Metastasis Rev; 2022 Jun; 41(2):447-458. PubMed ID: 35419769
[TBL] [Abstract][Full Text] [Related]
11. 6-Phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 and 4: A pair of valves for fine-tuning of glucose metabolism in human cancer.
Yi M; Ban Y; Tan Y; Xiong W; Li G; Xiang B
Mol Metab; 2019 Feb; 20():1-13. PubMed ID: 30553771
[TBL] [Abstract][Full Text] [Related]
12. Synthesis of amide and sulfonamide substituted N-aryl 6-aminoquinoxalines as PFKFB3 inhibitors with improved physicochemical properties.
Boutard N; Białas A; Sabiniarz A; Guzik P; Banaszak K; Biela A; Bień M; Buda A; Bugaj B; Cieluch E; Cierpich A; Dudek Ł; Eggenweiler HM; Fogt J; Gaik M; Gondela A; Jakubiec K; Jurzak M; Kitlińska A; Kowalczyk P; Kujawa M; Kwiecińska K; Leś M; Lindemann R; Maciuszek M; Mikulski M; Niedziejko P; Obara A; Pawlik H; Rzymski T; Sieprawska-Lupa M; Sowińska M; Szeremeta-Spisak J; Stachowicz A; Tomczyk MM; Wiklik K; Włoszczak Ł; Ziemiańska S; Zarębski A; Brzózka K; Nowak M; Fabritius CH
Bioorg Med Chem Lett; 2019 Feb; 29(4):646-653. PubMed ID: 30626557
[TBL] [Abstract][Full Text] [Related]
13. A High-Throughput Screening Triage Workflow to Authenticate a Novel Series of PFKFB3 Inhibitors.
St-Gallay SA; Bennett N; Critchlow SE; Curtis N; Davies G; Debreczeni J; Evans N; Hardern I; Holdgate G; Jones NP; Leach L; Maman S; McLoughlin S; Preston M; Rigoreau L; Thomas A; Turnbull AP; Walker G; Walsh J; Ward RA; Wheatley E; Winter-Holt J
SLAS Discov; 2018 Jan; 23(1):11-22. PubMed ID: 28945981
[TBL] [Abstract][Full Text] [Related]
14. 6-Phosphofructo-2-kinase (PFKFB3) promotes cell cycle progression and suppresses apoptosis via Cdk1-mediated phosphorylation of p27.
Yalcin A; Clem BF; Imbert-Fernandez Y; Ozcan SC; Peker S; O'Neal J; Klarer AC; Clem AL; Telang S; Chesney J
Cell Death Dis; 2014 Jul; 5(7):e1337. PubMed ID: 25032860
[TBL] [Abstract][Full Text] [Related]
15. Expression of inducible 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase/PFKFB3 isoforms in adipocytes and their potential role in glycolytic regulation.
Atsumi T; Nishio T; Niwa H; Takeuchi J; Bando H; Shimizu C; Yoshioka N; Bucala R; Koike T
Diabetes; 2005 Dec; 54(12):3349-57. PubMed ID: 16306349
[TBL] [Abstract][Full Text] [Related]
16. The synergistic effect of PFK15 with metformin exerts anti-myeloma activity via PFKFB3.
Liu X; Zhao Y; Zhang E; Yan H; Lv N; Cai Z
Biochem Biophys Res Commun; 2019 Jul; 515(2):332-338. PubMed ID: 31153642
[TBL] [Abstract][Full Text] [Related]
17. Regulation of glucose metabolism by 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatases in cancer.
Yalcin A; Telang S; Clem B; Chesney J
Exp Mol Pathol; 2009 Jun; 86(3):174-9. PubMed ID: 19454274
[TBL] [Abstract][Full Text] [Related]
18. Estradiol stimulates glucose metabolism via 6-phosphofructo-2-kinase (PFKFB3).
Imbert-Fernandez Y; Clem BF; O'Neal J; Kerr DA; Spaulding R; Lanceta L; Clem AL; Telang S; Chesney J
J Biol Chem; 2014 Mar; 289(13):9440-8. PubMed ID: 24515104
[TBL] [Abstract][Full Text] [Related]
19. Structure-based design of small-molecule ligands of phosphofructokinase-2 activating or inhibiting glycolysis.
Pyrkov TV; Sevostyanova IA; Schmalhausen EV; Shkoporov AN; Vinnik AA; Muronetz VI; Severin FF; Fedichev PO
ChemMedChem; 2013 Aug; 8(8):1322-9. PubMed ID: 23813838
[TBL] [Abstract][Full Text] [Related]
20. Expression of PFKFB3 and Ki67 in lung adenocarcinomas and targeting PFKFB3 as a therapeutic strategy.
Li X; Liu J; Qian L; Ke H; Yao C; Tian W; Liu Y; Zhang J
Mol Cell Biochem; 2018 Aug; 445(1-2):123-134. PubMed ID: 29327288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
